Synapse - Beatriz Wills Sanin

Results (17)

Prognostic impact of measurable residual disease evaluated by next generation flow and PET-CT in clinical practice at Fundación Santa Fe de Bogotá Hospital, Colombia

Meeting Abstract

Romero Prieto, M.; Melo Arias, A.; Oros, J. G.; Ovalle, N. T.; Ucros, G.; Galvis, K.; Martinez, D.; Cuellar, G.; Saavedra, C.; Martin, L.; more...
Blood (2024)

Fulltext@MSK | Save

Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma

Journal Article

Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G.; Fregonese, B.; Wills, B.; Bedmutha, A.; Alarcon Tomas, A.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Comparison of bendamustine versus fludarabine/cyclophosphamide lymphodepletion in adult patients receiving CD19 CAR-T cell therapy

Meeting Abstract

Landego, I.; Nemirovsky, D.; Devlin, S. M.; Wills, B.; Parascondola, A.; Saldia, A.; Dahi, P. B.; Tomas, A. A.; Ip, A.; Suh, H. C.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of response to systemic bridging therapy on clinical outcomes and cytokine profiles in patients receiving CD19-CAR T-cell therapy for B-cell lymphoma

Meeting Abstract

Wills, B.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Parascondola, A.; Saldia, A.; Imber, B. S.; Tomas, A. A.; Landego, I.; Lin, R. J.; more...
Blood (2023)

Fulltext@MSK | Save

Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome

Meeting Abstract

Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
Blood (2023)

Fulltext@MSK | Save

Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma

Meeting Abstract

Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma

Meeting Abstract

Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome

Meeting Abstract

Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Occult recurrent breast cancer masquerading as thrombotic thrombocytopenic purpura

Journal Article

Wills-Sanin, B.; George, J. N.; Boiocchi, L.; Soff, G. A.; Mones, J. V.
American Journal of Hematology (2023)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save